

Encorafenib + cetuximab + mFOLFOX6 BREAKWATER

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



QoL data pending



Serious and disabling adverse effects



Other adjustments



Encorafenib + cetuximab + mFOLFOX6 BREAKWATER

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
Therapeutic Indication: Encorafenib with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.
Experimental Arm: Encorafenib + cetuximab + mFOLFOX6
Control Arm: SOC (mFOLFOX6 + FOLFOXIRI or CAPOX) ± bevacizumab

